Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Pushing boundaries: Innovating ultrafast ultrasound imaging to explore genotype-phenotype interplay in young hypertrophic cardiomyopathy – Real-time diagnosis and personalized management

Project description

New tech to catch heart failure before it strikes

Hypertrophic cardiomyopathy (HCM) is a primary cause of sudden cardiac death in young adults. Although genetic advances have been made, serious difficulties remain, making early and accurate risk prediction crucial. With this in mind, the ERC-funded 5D ULTRAFAST-HCM project aims to introduce 5D ultrafast ultrasound imaging, which combines full volumetric heart echography with automatic AI analysis in real-time. By measuring myocardial stiffness, fibre disarray and microperfusion, it is hoped that high-risk patients will be identified before symptoms show. The project will improve imaging, confirm predictive biomarkers and build a risk model that can help doctors monitor, treat and protect young HCM patients.

Objective

Hypertrophic cardiomyopathy (HCM) is the most common form of cardiomyopathy, affecting 1 in 500 individuals globally. When HCM presents in childhood, adolescence, or early adulthood (0-30yo), it carries a high risk of morbidity and mortality, threatening young lives. Notably, HCM is a leading cause of sudden cardiac death (SCD) in adolescents and young adults without prior warning – a devastating condition affecting over 8000 European youths per year.
Despite genetic advances, this knowledge has yet to prevent HCM progression or major complications like arrhythmias, stroke, heart failure, or SCD. Early prediction of adverse outcomes is crucial to identify patients who may benefit from advanced therapies like implantable cardioverter-defibrillators (ICD) and heart transplantation.
5D ULTRAFAST-HCM will develop new biomarkers using advanced ultrasound to address the limitations of 2D ultrafast ultrasound imaging (UUI) in capturing the heart's complex 3D structure over cardiac cycles (4D), emphasizing the need for volumetric imaging. It will develop innovative 5D-UUI technology (4D with real-time AI-driven post-processing) for unprecedented whole-heart imaging, enabling assessment of new biomarkers. Preliminary data show that increased myocardial stiffness, abnormal fiber organization, and reduced microperfusion are key indicators in young HCM patients. We hypothesize that these factors, quantified through 5D-UUI, are directly linked to adverse outcomes. We will (i) refine 5D-UUI for clinical use, automate acquisition and analysis, (ii) validate new biomarkers predicting high-risk cases, and (iii) develop a new risk prediction model for improved ICD indication.
5D ULTRAFAST-HCM will establish this groundbreaking bedside imaging technology and revolutionize patient management. Its success will create a pioneering diagnostic tool that simplifies data collection, enhances patient experience, and offers AI-driven, operator-independent analysis for precise risk assessment.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2025-STG

See all projects funded under this call

Host institution

CHU HOPITAUX DE BORDEAUX
Net EU contribution
€ 1 312 425,00
Address
RUE DUBERNAT 12
33404 Talence
France
Region
Nouvelle-Aquitaine Aquitaine Gironde
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 1 499 425,00

Beneficiaries (2)